Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to r...
Source: BMC Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Milana Bergamino Sirv én, Adela Fernández-Ortega, Agostina Stradella, Idoia Morilla, Catalina Falo, Silvia Vázquez, Roser Castany, Rafael Villanueva, Sabela Recalde, Valentí Navarro Pérez, Miguel Gil-Gil and Sonia Pernas Tags: Research article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Spain Health | Study